KPIs & Operating Metrics(New)
Growth Metrics

Abbott Laboratories (ABT) Net Income towards Common Stockholders (2016 - 2025)

Abbott Laboratories' Net Income towards Common Stockholders history spans 17 years, with the latest figure at $1.8 billion for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 80.76% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $6.5 billion, down 51.32%, while the annual FY2025 figure was $6.5 billion, 51.32% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $1.8 billion at Abbott Laboratories, up from $1.6 billion in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $9.2 billion in Q4 2024 and bottomed at $1.0 billion in Q4 2022.
  • The 5-year median for Net Income towards Common Stockholders is $1.6 billion (2023), against an average of $2.0 billion.
  • The largest annual shift saw Net Income towards Common Stockholders soared 8825.0% in 2021 before it tumbled 80.76% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $2.0 billion in 2021, then crashed by 47.85% to $1.0 billion in 2022, then surged by 54.31% to $1.6 billion in 2023, then soared by 478.98% to $9.2 billion in 2024, then crashed by 80.76% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Net Income towards Common Stockholders are $1.8 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.8 billion (Q2 2025).